Overview

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Status:
Active, not recruiting

Trial end date:
2021-04-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc (CIZ) in a multivitamin combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated squamous cell carcinoma of the oral cavity or soft palate at a median of 3 years

Phase:

Phase 3

Details

Lead Sponsor:

CEL-SCI Corporation

Collaborators:

Orient Europharma Co., Ltd.
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Treatments:

Cisplatin
Cyclophosphamide
Indomethacin